Ocugen Inc Revenue Growth Rates (OCGN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ocugen Inc   (NASDAQ: OCGN)
 

OCGN's Revenue Growth by Quarter and Year

Ocugen Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OCGN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 1.49
1st Quarter March 1.53
FY 3.02





OCGN Revenue second quarter 2026 Y/Y Growth Comment
Ocugen Inc achieved in the second quarter 2026, above Company average Revenue improvement of 8.61% year on year, to $ 1.49 millions.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 30 other companies have achieved higher Revenue growth. While Ocugen Inc ' s Revenue increase of 8.61% ranks overall at the positon no. 1336 in the second quarter 2026.


OCGN Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - - -46.1 % -
3rd Quarter September - 53.51 % -69.19 % 687.23 %
2nd Quarter June 8.61 % 20.18 % 132.65 % -23.44 %
1st Quarter March 3.38 % 46.53 % 129.55 % -12 %
FY   - 8.89 % -32.95 % -

Financial Statements
Ocugen Inc 's second quarter 2026 Revenue $ 1.49 millions OCGN's Income Statement
Ocugen Inc 's second quarter 2025 Revenue $ 1.37 millions Quarterly OCGN's Income Statement


OCGN Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - - -33.33 % -61.89 %
3rd Quarter September - 27.74 % 0 % 655.1 %
2nd Quarter June -2.75 % -7.43 % 12.87 % 11.36 %
1st Quarter March - 94.74 % -28.37 % -
FY (Year on Year)   - 8.89 % -32.95 % -


Back to OCGN Growth rate Comparisons >> Back to OCGN Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #31
Healthcare Sector #233
Overall #1336

Revenue Y/Y Growth Statistics
High Average Low
8.83 % -36.1 % -61.97 %
(Dec 31 2025)   (Dec 31 2024)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #31
Healthcare Sector #233
Overall #1336
Revenue Y/Y Growth Statistics
High Average Low
8.83 % -36.1 % -61.97 %
(Dec 31 2025)   (Dec 31 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Ocugen Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
662.68 % 31.59 % -100 %
(Sep 30 2023)  


OCGN's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Ocugen Inc disclosed fall in Revenue from the first quarter by -2.75% to $ 1.49 millions, from $ 1.53 millions achived in the previous reporting period.

But that's not important problem, as Ocugen Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Ocugen Inc 's Revenue growth quarter on quarter, overall rank is 2194.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #35
Healthcare Sector #279
Overall #2194
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #35
Healthcare Sector #279
Overall #2194
Revenue Q/Q Growth Statistics
High Average Low
662.68 % 31.59 % -100 %
(Sep 30 2023)  


OCGN's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Ocugen Inc disclosed fall in Revenue from the first quarter by -2.75% to $ 1.49 millions, from $ 1.53 millions achived in the previous reporting period.

But that's not important problem, as Ocugen Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Ocugen Inc 's Revenue growth quarter on quarter, overall rank is 2194.


Ocugen Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 4.58 $ 4.47 $ 4.41 $ 5.37 $ 4.75
Y / Y Revenue Growth (TTM) -3.66 % -1.26 % 8.83 % 14.26 % -34.54 %
Year on Year Revenue Growth Overall Ranking # 3614 # 2400 # 2409 # 2273 # 0
Seqeuential Revenue Change (TTM) 2.58 % 1.18 % -17.82 % 12.96 % 5.13 %
Seq. Revenue Growth (TTM) Overall Ranking # 1336 # 850 # 2432 # 2299 # 3199


Cumulative Revenue growth Comment
Ocugen Inc 's cumulative 12 months Revenue continue to decrease, but on the faster rate at -3.66% year on year, at Jun 30 2026 compare to the -1.26% decrease at Mar 31 2026. If the Ocugen Inc 's fiscal year would end at Jun 30 2026, annual Revenue would be $5 millions.

In the Healthcare sector 509 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2400 to 3614.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 31
Healthcare Sector # 510
Overall # 3614

Revenue TTM Y/Y Growth Statistics
High Average Low
8.83 %
 -36.1 %
-61.97 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 31
Sector # 233
S&P 500 # 1336
Cumulative Revenue growth Comment
Ocugen Inc 's cumulative 12 months Revenue continue to decrease, but on the faster rate at -3.66% year on year, at Jun 30 2026 compare to the -1.26% decrease at Mar 31 2026. If the Ocugen Inc 's fiscal year would end at Jun 30 2026, annual Revenue would be $5 millions.

In the Healthcare sector 509 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2400 to 3614.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 31
Healthcare Sector # 510
Overall # 3614

Revenue TTM Y/Y Growth Statistics
High Average Low
8.83 %
-36.1 %
-61.97 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 31
Sector # 233
S&P 500 # 1336




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
OCGN's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Penumbra Inc14.90%$ 14.904 millions
Rockwell Medical inc 14.69%$ 14.687 millions
Sbc Medical Group Holdings Incorporated14.36%$ 14.363 millions
Nuwellis Inc 14.14%$ 14.145 millions
West Pharmaceutical Services Inc 13.89%$ 13.892 millions
Edwards Lifesciences Corporation13.66%$ 13.657 millions
Indivior Pharmaceuticals Inc 13.58%$ 13.576 millions
Talkspace Inc 13.56%$ 13.556 millions
Atricure Inc 13.38%$ 13.376 millions
Dexcom Inc 13.11%$ 13.105 millions
Sanara Medtech Inc 13.03%$ 13.028 millions
Bausch Health Companies Inc 12.73%$ 12.727 millions
Vertex Pharmaceuticals Inc12.45%$ 12.453 millions
Genedx Holdings Corp 12.30%$ 12.304 millions
Profound Medical Corp 12.30%$ 12.302 millions
Xenetic Biosciences Inc 11.99%$ 11.986 millions
Biolife Solutions Inc 11.98%$ 11.978 millions
Repligen Corp11.93%$ 11.933 millions
Medline Inc 11.60%$ 11.603 millions
Earth Science Tech Inc 11.56%$ 11.556 millions
Immucell Corporation11.50%$ 11.501 millions
Harrow Inc 11.26%$ 11.256 millions
Rapid Micro Biosystems Inc 10.91%$ 10.906 millions
Livanova Plc10.80%$ 10.797 millions
Cerus Corporation10.52%$ 10.517 millions
Interpace Biosciences Inc 10.33%$ 10.331 millions
Warby Parker Inc 10.25%$ 10.253 millions
Neuronetics Inc 10.25%$ 10.249 millions
Elanco Animal Health Incorporated10.23%$ 10.234 millions
Quest Diagnostics Inc10.21%$ 10.214 millions


About Ocugen Inc Revenue Growth Rates (OCGN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ocugen Inc (CIK 1372299).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-054057
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ocugen Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.